Can radiation prime the immune system to fight blood cancer?
In 1953, a physician named RH Mole published a paper in the British Journal of Radiology describing a surprising phenomenon he called the
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
Multiple Myeloma
News
Multiple Myeloma
News
FDA extends review for DREAMM-7, DREAMM-8 therapy in myeloma
The US Food and Drug Administration (FDA) extended the review timeline for the Biologics License Application for the belantamab mafodotin combinations investigated in
SOHO 2025
Meeting News
Myelodysplastic Syndromes
News
SOHO Insider Podcast
SOHO President Phillip Scheinberg talks with Saad Usmani on SOHO 2025
Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Phillip Scheinberg, MD, president of the Society of
EHA 2025
Meetings / Conferences
News
Phase 1 subcutaneous blinatumomab safe, effective in R/R B-ALL
Elias Jabbour, MD, leukemia professor in the University of Texas MD Anderson Cancer Center, discusses the phase 1/2 expansion study of subcutaneous blinatumomab
EHA 2025
Myeloproliferative Neoplasms
Video Interviews
Novel therapy INCA in ET shows positive results in early-phase data
Lucia Masarova, MD, an assistant professor in the Department of Leukemia at the University of Texas MD Anderson, discusses the 2025 EHA late-breaking
Multiple Myeloma
News
FDA panel rejects blenrep combo in myeloma over safety, dosing concerns
The combinations, bortezomib and dexamethasone and pomalidomide and dexamethasone, were evaluated in adults with R/R multiple myeloma who have received at least one
SOHO 2025
News
Video Interviews
Society Updates
We are in full countdown mode to SOHO 2025
Register at soho.click/2025.
EHA 2025
News
Heme professionals report high burnout in EHA member survey
Long hours, lack of support, and poor management were identified as contributors to burnout among hematology professionals, according to a survey presented at
Lymphoma
Aggressive B-Cell Lymphomas
News
Early data support glofitamab combo in high-risk LBCL
The CD20xCD3 bispecific antibody glofitamab was shown to have durable responses when combined with Pola-R-CHP or R-CHOP, according to results from the phase
EHA 2025
News
Video Interviews
Dr. Masarova discusses SURPASS-ET study at EHA 2025
Lucia Masarova, MD, assistant professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston, discusses